The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor olaparib to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.
Browsing: drug development
A genetics study has unearthed an unexpected new drug target for acute myeloid leukaemia that could open new avenues to develop effective treatments.
Researchers from the Case Western Reserve University (OH, USA) have demonstrated how a computer program can suggest novel cancer treatments.
Researchers have demonstrated that breast cancer can resurface 15 years after treatment, epigenetic editing has revealed a surprising insight into early breast cancer development and two breakthrough CDK4/6-inhibitor drugs have been approved for advanced breast cancer.
In this interview with the Vice President of Global Development at Amgen we take a more in-depth look at the trastuzumab data, an oncology biosimilar medicine.
In this interview discover further details of the JAVELIN Merkel 200 that led to the approval of the first immunotherapy treatment indicated in the EU and the first US FDA-approved systemic therapy for merkel cell carcinoma.
This article first reviews the brief achievements in using albendazole to treat parasites and cancers, and summarizes the basic mechanisms of action of albendazole.
Listen to this podcast to discover more about the UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).
What is the potential clinical significance of the results of the FLAURA trial presented at ESMO? Find out in our exclusive interview.
A nationwide study across Ireland revealed that the vast majority of patients do not understand the core concepts underpinning a clinical trial.